Journal Section:
Erratum

In the article entitled “EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)” [Obes Facts. 2024;17(4):374–444; DOI: 10.1159/000539371], by the European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO), the formulation listed in the original text was correct but was based on a previous generation of lab analyzers. With the introduction of a new generation of lab analyzers for this test, the formula was slightly modified to obtain the ELF (enhanced liver fibrosis) test. Since most laboratories worldwide use this new formulation and the referenced meta-analysis was primarily based on studies using this new formulation, the authors request that the following paragraph on page 13 be updated to provide the most up-to-date formulation to the readers:

“The ELF (enhanced liver fibrosis) test produces a single score based on quantitative measurements of three serum markers of extracellular collagen metabolism. ELF = 2.494 + 0.846 In(hyaluronic acid) + 0.735 In(amino-terminal propeptide of type III procollagen [PRO-C3]) + 0.391 In(tissue inhibitor of metalloproteinases 1) according to the ADVIA Centaur CP System [147].

In a meta-analysis of 63 studies, ELF showed a relatively high performance in detecting significant fibrosis, advanced fibrosis or cirrhosis (AUROCs 0.811, 0.812 and 0.810, respectively) [148].”

should be updated to:

“The ELFTM (enhanced liver fibrosis) test produces a single score based on quantitative measurements of three serum markers of extracellular collagen metabolism [147]. ELF = 2.278 + 0.851 × In(hyaluronic acid [HA]) + 0.751 × In(amino-terminal propeptide of type III procollagen [PIIINP]) + 0.394 × In(tissue inhibitor of metalloproteinase 1 [TIMP-1]) as measured on the ADVIA Centaur XP/XPT system, Atellica IM Analyzer and Atellica CI Analyzer.

In a meta-analysis of 63 studies, ELF showed a relatively high performance in detecting significant fibrosis, advanced fibrosis or cirrhosis (AUROCs 0.811, 0.812 and 0.810, respectively) [148].”

Please note that this is a joint publication with the Journal of Hepatology entitled “EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)” (journal-of-hepatology.eu).

The original online article has been updated to reflect this.

© 2024 The Author(s) Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial